Just reported
From Stryker's results release of 29 octobre 2026; its quarterly report has since been filed.
Actual
6,52B $US
+7,6 % y/y
-1,0 % q/q
Guided
—
No guide given
Actual
1,96 $US
-12 % y/y
-41 % q/q
Guided
—
No guide given
Actual
1,03B $US
-8,9 % y/y
-38 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Stryker is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Les parts du chiffre d'affaires sont des estimations pour nine months ended 2026-09-30, pas des chiffres tirés d'un document officiel.
Surgical instruments and navigation systems
Powered surgical tools and navigation equipment that help surgeons carry out procedures.
Endoscopy and communications equipment
Cameras and related equipment that let clinicians view inside the body, alongside systems that connect operating-room equipment.
Patient and emergency-care equipment
Hospital beds, patient-handling equipment, emergency monitors and defibrillators, intensive-care disposables, and clinician communication systems.
Minimally invasive vascular devices
Catheters and other devices used in minimally invasive treatment of stroke and venous blood clots.
Brain and cranial surgery products
Products for brain and open-skull surgery, including synthetic bone grafts and products used to treat spinal bone conditions.
Joint and trauma implants and robotic surgery systems
Hip, knee, shoulder, ankle and trauma implants, plus robotic systems and surgical tools used in these operations.
Stryker makes equipment used during operations and in hospital wards, including cameras, surgical instruments, beds, emergency devices and systems that help hospital staff communicate. It also makes minimally invasive devices to treat strokes and blood clots, plus implants and robotic systems used in joint replacement and trauma surgery. It sells mainly to doctors, hospitals and other healthcare facilities, both directly and through distributors.
Construit à partir des documents déposés par Stryker Corp. auprès de la Securities and Exchange Commission (SEC), le gendarme boursier américain. Les chiffres sont tels que publiés, l’historique par action étant retraité sur la base d’actions d’aujourd’hui. Ceci décrit une entreprise — ce n’est pas un conseil en investissement ni une recommandation d’acheter ou de vendre.
309,64 $US-0,9 %clôture 13 nov.
Chiffres jusqu’au 30 septembre 2026, issus du 10-Q déposé le 30 octobre 2026
Stryker sells operating-room and hospital-care equipment and minimally invasive stroke and clot-treatment devices to hospitals and clinicians, alongside implants and robots for joint surgery.
Grade A+
La bande sous le cours montre la note à chaque date, établie uniquement à partir des documents publics à ce moment-là.
Affichage de 2 trimestres sur 41 de l’historique des notes de Stryker Corp.. Les 39 autres remontent jusqu’à octobre 2016.